Clinical Sites

Our current approach to the clinical management of COPD is focused on the treatment of moderate to severe disease. To truly bend the needle in reducing morbidity and mortality we need to focus on the prevention and treatment of pre-COPD and mild disease. The SOURCE early COPD study will provide critical information about the beginnings of COPD that will facilitate that shift.

The SOURCE study’s focus on the early development of COPD and comprehensive, longitudinal assessment of future participants offers a unique opportunity to answer many important questions related to the pathogenesis of COPD. I will be honored and happy to contribute to a successful study build up.

Understanding how some people who are 'at risk' go on to develop COPD is a crucial step in preventing COPD.

The COVID-19 pandemic has made the world more aware of the importance of lung health than ever. This study offers participants an opportunity to better understand their own lung health and for researchers to better understand factors that contribute to lung health and disease.

COPD is a leading cause of death among smokers, yet we know little about the origins of early COPD. Your participation in the source study will help us understand which smokers are at risk of progression to COPD and the factors that increase this risk.

We know that some younger cigarette smokers are diagnosed with COPD while others may smoke for years without developing COPD. This study will shed light on what contributes to such different outcomes and will help me explain to my patients whether they are at risk for COPD.

Chronic lung diseases have an incredible impact on general health and quality of life. COPD is a common problem worldwide, which affects all races and genders. This study provides us with the opportunity to better understand factors that affect lung health and potentially develop future therapeutic strategies to change the course of the disease.